RT Journal Article
SR Electronic
T1 GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.17.20133579
DO 10.1101/2020.06.17.20133579
A1 Luis Corral-Gudino
A1 Alberto Bahamonde
A1 Francisco Arnaiz-Revillas
A1 Julia Gómez-Barquero
A1 Jesica Abadía-Otero
A1 Carmen García-Ibarbia
A1 Víctor Mora
A1 Ana Cerezo-Hernández
A1 José L. Hernández
A1 Graciela López-Muñíz
A1 Fernando Hernández-Blanco
A1 Jose M. Cifrián
A1 Jose M. Olmos
A1 Miguel Carrascosa
A1 Luis Nieto
A1 María Carmen Fariñas
A1 José A. Riancho
A1 for the GLUCOCOVID investigators
A1 Alberto Bahamonde
A1 Fernando Hernández-Blanco
A1 Cristina Buelta-González
A1 Luis A. Marcos-Martínez
A1 Ana I. Martínez-Vidal
A1 Pilar R.l Dosantos-Gallego
A1 Jesús Pérez-Sagredo
A1 Silvia Sandomingo-Freire
A1 Rebeca Muñumer-Blázquez
A1 Antonio Paredes-Mogollo
A1 Elena Brague-Allegue
A1 Miguel Carrascosa
A1 Juan L. García-Rivero
A1 José A. Riancho
A1 José M. Olmos
A1 Carmen Fariñas
A1 José M. Cifrian
A1 Carmen García-Ibarbia
A1 Jose L. Hernández
A1 Francisco Arnaiz-Revillas
A1 Victor Mora
A1 Sara Nieto
A1 Juan Ruiz-Cubillán
A1 Arancha Bermúdez
A1 Javier Pardo
A1 Carlos Amado
A1 Andrés Insunza
A1 Aritz Gil
A1 Teresa Diaz-Terán
A1 Marina Fayos
A1 Miguel A. Zabaleta
A1 Juan J. Parra
A1 Luis Corral-Gudino
A1 Julia Gómez-Barquero
A1 Jesica Abadía-Otero
A1 Ana Cerezo-Hernández
A1 Graciela López-Muñíz
A1 Angela Ruíz-de-Temiño-de-la-Peña
A1 C. Ainhoa Arroyo-Domingo
A1 Javier Mena-Martín
A1 Pablo Miramontes-González
A1 Ana E Jiménez-Masa
A1 Luis Pastor-Mancisidor
A1 Tanía M Álvaro-de-Castro
A1 María Cruz Pérez-Panizo
A1 Tomás Ruíz-Albi
A1 C Gema de-la-Colina-Rojo
A1 María Andrés-Calvo
A1 Andrea Crespo-Sedano
A1 Begoña Morejón-Huerta
A1 Laisa S. Briongos-Figuero
A1 Julio F Frutos-Arriba
A1 Javier Pagán-Buzo
A1 Miriam Gabella-Martín
A1 Marta Cobos-Siles
A1 Ana Gómez-García
A1 Luis Nieto
YR 2020
UL http://medrxiv.org/content/early/2020/06/18/2020.06.17.20133579.abstract
AB Background We aimed to determine whether a 6-day course of intravenous methylprednisolone (MP) improves outcome in patients with SARS CoV-2 infection at risk of developing Acute Respiratory Distress Syndrome (ARDS).Methods Multicentric, partially randomized, preference, open-label trial, including adults with COVID-19 pneumonia, impaired gas exchange and biochemical evidence of hyper-inflammation. Patients were assigned to standard of care (SOC), or SOC plus intravenous MP [40mg/12h 3 days, then 20mg/12h 3 days]. The primary endpoint was a composite of death, admission to the intensive care unit (ICU) or requirement of non-invasive ventilation (NIV).Results We analyzed 85 patients (34, randomized to MP; 22, assigned to MP by clinician’s preference; 29, control group). Patients’ age (mean 68±12 yr) was related to outcome. The use of MP was associated with a reduced risk of the composite endpoint in the intention-to-treat, age-stratified analysis (combined risk ratio -RR-0.55 [95% CI 0.33-0.91]; p=0.024). In the per-protocol analysis, RR was 0.11 (0.01-0.83) in patients aged 72 yr or less, 0.61 (0.32-1.17) in those over 72 yr, and 0.37 (0.19-0.74, p=0.0037) in the whole group after age-adjustment by stratification. The decrease in C-reactive protein levels was more pronounced in the MP group (p=0.0003). Hyperglycemia was more frequent in the MP group.Conclusions A short course of MP had a beneficial effect on the clinical outcome of severe COVID-19 pneumonia, decreasing the risk of the composite end point of admission to ICU, NIV or death.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudraCT number: 2020-001934-37Funding StatementNo specific fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite de Etica en Investigacion con Medicamentos de CantabriaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequest from authors